ABT trades against a final fair-value range of $87.24-$127.26, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $87.2, high $127, with mid-point at $107.
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.
§1 الملخص التنفيذي
Composite fair value $107 with high case $127.
Implied upside of 26.9% to fair value.
Moat 9/10 · confidence 88/100 · Mature dividend.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$107
Margin of safety
+21.2%
Confidence
88/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$84.32Price
Low $87.24
Mid $107.02
High $127.26
ABT trades against a final fair-value range of $87.24-$127.26, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Diversified portfolio across high-margin medical
Diversified portfolio across high-margin medical devices, diagnostics, and nutrition.
Entrenched global distribution networks and
Entrenched global distribution networks and vast regulatory expertise.
Cycle upside
Aging demographic tailwinds and normalized elective procedure volumes drive sustained, high-margin medical device demand.
ABT (ABT)'s balance sheet section reports total assets, total liabilities, shareholders' equity, and the structure of debt versus cash so leverage and liquidity can be read directly.
Balance-sheet quality is tracked through net-debt position, interest-coverage trends, and changes in working capital. Material deterioration is flagged in the numbers-analysis subsection together with the income-statement read.
We report total debt and net debt (debt minus cash) on each balance-sheet snapshot. The trajectory across five years lets the reader judge whether debt is being reduced, held steady, or stepped up to fund operations.
Shareholders' equity is reported alongside book-value-per-share metrics where applicable. Buyback-driven equity declines are separated from operating-loss-driven declines so the reader can interpret the change correctly.
FAQ
ABT — frequently asked questions
Based on our latest analysis, ABT looks meaningfully undervalued. The current price is $84.3 versus a composite fair-value midpoint of $107 (range $87.2–$127), which implies roughly 26.9% upside to the midpoint.
Our composite fair-value range for ABT is $87.2–$127, with a midpoint of $107. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for ABT's archetype.
Our current rating for ABT is Strong Buy with a confidence score of 88/100. ABT is rated Strong Buy at $84.32 versus the reconciled fair value midpoint of $107.02, implying +26.92% upside/downside. Confidence is separately disclosed at 88/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for ABT are: Libre Market Share Loss; Nutrition Margin Collapse; Dividend Sustainability Crisis. The single biggest risk is Libre Market Share Loss: Next-gen competitive continuous glucose monitors or GLP-1 drug advancements severely erode FreeStyle Libre adoption, cratering high-margin medical device growth.
Our current rating for ABT is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($87.2–$127) versus the current price of $84.3.
ABT is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ABT.